HGH Fragment 176-191 side effects by evidence tier: the oral AOD-9604 trial tolerability data, what rodent work adds, what self-report cannot show, and the injectable-route gap.
HGH Fragment 176-191 is the C-terminal sixteen residues of human growth hormone, synthesised as a standalone peptide. Searches for its side effects return either a reassurance that it has none or a list copied from growth hormone. Neither is right. The fragment does not act on the GH axis, so growth hormone's adverse-effect profile does not apply; and its reputation for safety rests on a specific, bounded dataset — the oral AOD-9604 trials run by Metabolic Pharmaceuticals in the early 2000s — that says nothing about the injectable route research-grade material is used by.
This page separates controlled human trials, animal work and uncontrolled self-report. It sits beside the HGH Fragment 176-191 profile and the AOD-9604 vs HGH Fragment 176-191 comparison, which explains why one peptide carries two names. It is a research reference, not advice.
The fragment is one of few research peptides with a genuine human safety dataset, because a company published the tolerability result after the efficacy result failed. Stier, Vos and Kenley, Journal of Endocrinology and Metabolism (2013), pooled six clinical trials of AOD-9604 covering roughly nine hundred participants. The peptide was given as an oral tablet once daily at doses reported from 1 mg to 30 mg, for up to twelve weeks.
The pooled analysis reported an adverse-event profile comparable to placebo, no effect on glucose or insulin, no rise in IGF-1, and no anti-AOD-9604 antibodies. Those negative findings were not incidental: the trials were designed to show that the fragment lacks growth hormone's diabetogenic and growth-promoting actions, and they did. The largest study in the pool — the twelve-week Phase 2b in about three hundred obese adults at 1 mg daily — was well tolerated in the same twelve weeks in which it failed its primary weight-loss endpoint.
That is a real finding, stated precisely: oral tablets, twelve weeks or less, placebo-comparable adverse events, no metabolic or immunogenic signal. Each qualifier limits what the data can support.
Nearly everything a researcher handling the injectable material would want to know:
The published record supports a narrow claim — oral AOD-9604 was well tolerated in short trials — and not the broader one usually made.
The rodent literature from the Monash group and Metabolic Pharmaceuticals (Heffernan and colleagues, Endocrinology and International Journal of Obesity, 2001) reported no toxicity at the doses studied, roughly 0.25 to 2 mg/kg per day for two to three weeks. Glucose tolerance was not impaired, IGF-1 did not rise, and the lipolytic effect persisted in β3-adrenergic-receptor knockout mice. A 2015 rabbit osteoarthritis study (Kwon and Park, Annals of Clinical and Laboratory Science) reported improved cartilage histology after weekly intra-articular injection; it was a single small efficacy study, not a safety study.
Animal tolerability is a floor, not a ceiling: it describes what was looked for in a handful of short protocols, and formal toxicology of the injectable fragment has not been published.
Community and vendor sources describe injection-site redness, swelling and tenderness, and occasional transient headache or fatigue in early use. These are uncontrolled, unblinded self-reports with no denominator, from material of unverified purity. They cannot establish incidence, causation or severity; they are hypotheses, not findings.
Because the fragment does not bind the growth hormone receptor with meaningful affinity and did not raise IGF-1 in any study, the class concerns attached to secretagogues — IGF-1 elevation, insulin resistance, fluid retention — are not expected, and the human trials did not find them. That describes what was measured over twelve weeks by mouth. It is not evidence that injected material is free of those effects, and it says nothing about effects never measured. "Looked for and not found" and "not looked for" remain different statements.
Some share of any reaction reported with unregulated peptide use plausibly traces to the vial rather than the molecule: synthesis impurities, truncated sequences, residual solvents, endotoxin load, or material degraded by a broken cold chain. The fragment adds one specific confound. Its two cysteines form a disulfide bridge in the pharmaceutical material, but the linear and oxidised forms have the same nominal sequence and masses two daltons apart, so a correctly labelled lot may still not be the species the trials used. A certificate of analysis with HPLC purity and a mass-spectrometry identity check is the only way to separate compound effects from product effects; the lab-testing page explains what Canada Peptides tests. Storage follows the cold-chain and shelf-life guide: lyophilised at 2–8 °C in the dark, reconstituted solutions refrigerated and used within weeks, no repeated freeze–thaw.
HGH Fragment 176-191 has no Health Canada market authorisation and no Drug Identification Number; it has not been reviewed for safety or efficacy, and it is sold in Canada for research use only. In September 2023 the U.S. FDA placed AOD-9604 — the same sequence — in category 2 of its evaluation of bulk substances for section 503A compounding, citing insufficient safety data for the compounded, injectable form: the most direct regulatory statement on the injectable route that exists. The WADA Prohibited List names both hGH 176-191 and AOD-9604 under S2, so the fragment is prohibited for tested athletes at all times. Research-grade material is listed here as HGH FRAG 176-191 5MG.
Does HGH Fragment 176-191 have a documented side-effect profile? For oral AOD-9604 over up to twelve weeks, yes: a pooled analysis of six trials in roughly nine hundred participants reported adverse events comparable to placebo. For the injectable fragment used in research, no controlled human data exist.
Did the human trials find any metabolic effects? No. The pooled analysis reported no change in glucose or insulin, no rise in IGF-1 and no antibody formation. The trials were designed to test for those effects because they are growth hormone's known liabilities.
Does the fragment carry growth hormone's side effects? It does not act on the growth hormone receptor or raise IGF-1, so the secretagogue-class effects are not expected and were not observed. That describes what was measured, not a safety guarantee for a different route and duration.
Why did the FDA restrict AOD-9604 if the trials were clean? The 2023 category 2 determination concerned compounded, injectable use and cited insufficient safety data for that form. The clean trials were oral.
Is this medical advice? No. HGH Fragment 176-191 is a research-grade material for laboratory use only, not for human or veterinary use. This page reports what published studies recorded; it is not a safety assurance, a dosing recommendation or a substitute for a licensed physician.
